Board meeting held on August 11, 2025
As filed · Ind-Swift Laboratories Limited has informed the Exchange regarding Board meeting held on August 11, 2025.
What happened
FactThe Board of INDSWFTLAB approved the audited financial results for the 4th Quarter and Financial Year ended March 31, 2025, including the Statement of Profit & Loss, Statement of Assets & Liabilities, and Statement of Cash Flow, both on a standalone and consolidated basis. The results have been reviewed by the Audit Committee and audited by the statutory auditors. Additionally, the Board approved the allotment of 14,20,000 redeemable preference shares to allottees from the…
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Demand
DelayedIn the second quarter we are expecting a major push from Arrotex on that Macrogol new molecule which we launched.
And in third and fourth quarter we see a lot of progress coming from Ibuprofen and Clarithromycin granules.
Change
FactImplication
CapitSignal interpretationWatch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- We expect FY27 to witness revenue growth of more than 50%. (management committed by FY27)
- A key milestone was the commercialization of the Viatris (USA), Manx (UK) and Arrotex (Australia) CDMO partner (management committed by FY27)
Evidence
- Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on August 11, 2025.(opens the original filing in a new tab)
- Earlier statement · Q1 FY27
- Latest statement · Q1 FY27
- Earlier statement · Q1 FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +5 quantified amount; +3 quantified percentage; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 75%